IL312274A - Compositions comprising ciprofloxacin and celecoxib - Google Patents
Compositions comprising ciprofloxacin and celecoxibInfo
- Publication number
- IL312274A IL312274A IL312274A IL31227424A IL312274A IL 312274 A IL312274 A IL 312274A IL 312274 A IL312274 A IL 312274A IL 31227424 A IL31227424 A IL 31227424A IL 312274 A IL312274 A IL 312274A
- Authority
- IL
- Israel
- Prior art keywords
- tablet according
- ciprofloxacin
- celecoxib
- previous
- tablet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163257130P | 2021-10-19 | 2021-10-19 | |
| PCT/IL2022/051096 WO2023067592A1 (en) | 2021-10-19 | 2022-10-18 | Compositions comprising ciprofloxacin and celecoxib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312274A true IL312274A (en) | 2024-06-01 |
Family
ID=85982158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312274A IL312274A (en) | 2021-10-19 | 2022-10-18 | Compositions comprising ciprofloxacin and celecoxib |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12097185B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4419099A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7857044B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102969898B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN118369097A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022370513B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3235348A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312274A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023067592A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10031043A1 (de) * | 2000-06-26 | 2002-02-14 | Bayer Ag | Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung |
| EP3641820B1 (en) | 2017-06-20 | 2022-12-28 | Neurosense Therapeutics Ltd. | Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases |
| US12527768B2 (en) | 2017-06-20 | 2026-01-20 | Neurosense Therapeutics Ltd. | Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases |
-
2022
- 2022-10-18 JP JP2024523514A patent/JP7857044B2/ja active Active
- 2022-10-18 EP EP22883107.9A patent/EP4419099A4/en active Pending
- 2022-10-18 CA CA3235348A patent/CA3235348A1/en active Pending
- 2022-10-18 KR KR1020247016529A patent/KR102969898B1/ko active Active
- 2022-10-18 CN CN202280081257.7A patent/CN118369097A/zh active Pending
- 2022-10-18 WO PCT/IL2022/051096 patent/WO2023067592A1/en not_active Ceased
- 2022-10-18 AU AU2022370513A patent/AU2022370513B2/en active Active
- 2022-10-18 IL IL312274A patent/IL312274A/en unknown
- 2022-10-18 US US18/047,289 patent/US12097185B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240090519A (ko) | 2024-06-21 |
| EP4419099A1 (en) | 2024-08-28 |
| CN118369097A (zh) | 2024-07-19 |
| AU2022370513B2 (en) | 2025-09-25 |
| US20230120880A1 (en) | 2023-04-20 |
| AU2022370513A1 (en) | 2024-05-16 |
| KR102969898B1 (ko) | 2026-05-28 |
| US12097185B2 (en) | 2024-09-24 |
| CA3235348A1 (en) | 2023-04-27 |
| JP2024539116A (ja) | 2024-10-28 |
| EP4419099A4 (en) | 2025-09-24 |
| JP7857044B2 (ja) | 2026-05-12 |
| WO2023067592A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3276962B2 (ja) | 安定な医薬組成物 | |
| JPH01100134A (ja) | 徐放性製剤 | |
| JP2005538105A (ja) | 水不溶性ポリマーおよび水溶性の小孔形成物質からなる２層により被覆された固体剤形の製造方法 | |
| UA109659C2 (xx) | Фармацевтичні композиції, що містять 4-аміно-5-фтор-3-$6-(4-метилпіперазин-1-іл)-1h-бензімідазол-2-іл]-1h-хінолін-2-ону лактату моногідрат | |
| HUP0203334A2 (hu) | Közvetlen kompresszióval előállított polimer tabletta magok | |
| JPH09500910A (ja) | パラセタモール及びドンペリドンのフィルムコーティング錠 | |
| EP2740471B1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
| TW201922230A (zh) | 控釋製劑 | |
| TW202139977A (zh) | 包括阿托伐他汀以及怡妥錠的雙層片劑及其製造方法 | |
| JPS5883618A (ja) | ニトロフラントイン投与剤 | |
| JP5208729B2 (ja) | 徐放性錠剤の製造方法 | |
| JP2022544167A (ja) | ニトロキソリンを含む医薬組成物、ニトロキソリン経口固形錠剤、その調製方法、及びその使用 | |
| WO2017101858A1 (zh) | 环苄普林之延释剂型 | |
| US5198228A (en) | Direct dry compressible acetaminophen tablet | |
| FI114610B (fi) | Menetelmä beta-fenyylipropiofenonijohdannaisia sisältävien retardmikrotablettien valmistamiseksi | |
| US5037658A (en) | Direct dry compressible acetaminophen composition | |
| TW201306881A (zh) | 緩釋對乙醯胺基酚調配物 | |
| WO2004017938A2 (en) | Nitrofurantoin controlled release dosage form | |
| US5130140A (en) | Method of making direct dry compressible acetaminophen composition | |
| RU2024111884A (ru) | Композиции, содержащие ципрофлоксакин и целекоксиб | |
| WO2017093890A1 (en) | Clobazam tablet formulation and process for its preparation | |
| JPH08325142A (ja) | ヨウ化イソプロパミド含有製剤 | |
| EP3052086A1 (en) | Pharmaceutical composition comprising low dose active pharmaceutical ingredient and preparation thereof | |
| EP1713452A2 (en) | Sustained release pharmaceutical composition of indapamide | |
| JP4884772B2 (ja) | 経口徐放性錠剤 |